Open AccessEngineered biomaterials for cancer immunotherapy
Author(s) -
Cai Lulu,
Xu Jialu,
Yang Zhenglin,
Tong Rongsheng,
Dong Ziliang,
Wang Chao,
Leong Kam W.
Publication year - 2020
Publication title -
medcomm
Language(s) - English
Resource type - Journals
ISSN - 2688-2663
DOI - 10.1002/mco2.8
Subject(s) - immunotherapy , transdermal , cancer immunotherapy , medicine , cancer , drug delivery , cancer therapy , immune system , cancer treatment , cancer research , immunology , nanotechnology , pharmacology , materials science
Although cancer immunotherapy is showing tremendous promise and has progressed to the clinic, it has only achieved sporadic efficacy, with only a fraction of patients benefitting from the therapy and with undesirable side effects due to poor selectivity and high doses. Localized delivery of immunomodulators to activate anticancer immunity in situ avoids overactivation of the systemic immune system and reduces side effects. Engineered biomaterials—implantable, injectable, or transdermal—fabricated into drug delivery devices are critical components for the development of localized cancer immunotherapies. In this review, we briefly summarize progress in the application of engineered biomaterials to the localized delivery of cancer immunotherapy.